Lacroix P, Portefaix O, Boucher M, Ramiandrisoa H, Dumas M, Ravon R, Christides C, Laskar M
Service de CTCV et angiologie, CHRU Dupuytren, Limoges.
Arch Mal Coeur Vaiss. 1994 Dec;87(12):1715-9.
Cerebral haemorrhage is the main life-threatening complication of oral anticoagulant therapy. In order to identify a means of prevention, the authors undertook a retrospective study of 68 consecutive cases of anticoagulant-related intracerebral haemorrhage. The mortality was 38.5%. The respective frequency of intracerebral haemorrhage, subarachnoid haemorrhage, acute and chronic subdural haematomas was 63.2, 16.2, 10.3 and 10.3%, respectively. On admission, nearly half the patients (53%) had prothrombin ratios inferior to 25%. A predisposing factor was found in 58% of cases: hypertension (30.6%), head injury (14.5%), alcoholism or drug interaction (11.2%), and one case of intracerebral aneurysm. A history of a transient ischaemic attack or of a cerebrovascular accident was found in 10.2% of cases and 11.7% had a previous anticoagulant related extracranial haemorrhage. The initial indications for oral anticoagulation were ischaemic heart disease (32%), atrial fibrillation (20.5%), secondary prevention of venous thromboembolic disease (17.6%) and primary prevention of venous thrombosis (11.7%). The duration of treatment for isolated ischaemic heart disease was over 6 months in all cases: the average duration of treatment was 12.4 months in phlebitis and pulmonary embolism. A critical review of the indications of treatment in the light of recent recommendations showed that if inappropriate indications were rare, the sometimes unnecessary prolongation of treatment was more common. Nearly half of these cases were receiving anticoagulants when the potential benefits were questionable at the time of the haemorrhagic complication. Clinical and biological follow-up is necessary for patients on anticoagulants; minor bleeding complications may be the prelude to major haemorrhage. Biological follow-up is based on control of the international normalised ratio.(ABSTRACT TRUNCATED AT 250 WORDS)
脑出血是口服抗凝治疗主要的危及生命的并发症。为了确定预防方法,作者对68例连续的抗凝相关脑出血病例进行了回顾性研究。死亡率为38.5%。脑出血、蛛网膜下腔出血、急性和慢性硬膜下血肿的各自发生率分别为63.2%、16.2%、10.3%和10.3%。入院时,近一半患者(53%)的凝血酶原比率低于25%。58%的病例发现有诱发因素:高血压(30.6%)、头部损伤(14.5%)、酗酒或药物相互作用(11.2%)以及1例脑内动脉瘤。10.2%的病例有短暂性脑缺血发作或脑血管意外病史,11.7%曾有抗凝相关的颅外出血。口服抗凝治疗的初始指征为缺血性心脏病(32%)、房颤(20.5%)、静脉血栓栓塞性疾病的二级预防(17.6%)和静脉血栓形成的一级预防(11.7%)。所有单纯缺血性心脏病病例的治疗持续时间均超过6个月:静脉炎和肺栓塞的平均治疗持续时间为12.4个月。根据近期建议对治疗指征进行严格审查发现,虽然不恰当的指征很少见,但有时不必要的治疗延长更为常见。在出血并发症发生时,这些病例中近一半在接受抗凝治疗,而此时潜在益处存疑。对抗凝患者进行临床和生物学随访很有必要;轻微出血并发症可能是大出血的前奏。生物学随访基于国际标准化比值的监测。(摘要截选至250词)